Innovative Translational Studies in Cholestatic Disorders

Nov 09 2025
Convention Center: Room 202, Level 2
11:00 AM - 12:30 PM

World Class Speakers

Kazumichi Abe, MD, PhD
Abstract Presenter

Kazumichi Abe, MD, PhD

Fukushima Medical University School of Medicine
Monika Sarkar, MD, FAASLD, MAS
Abstract Presenter

Monika Sarkar, MD, FAASLD, MAS

University of California, San Francisco
David N. Assis, MD
Abstract Presenter

David N. Assis, MD

Yale University
Monika Sarkar, MD, FAASLD, MAS
Moderator

Monika Sarkar, MD, FAASLD, MAS

University of California, San Francisco
David N. Assis, MD
Moderator

David N. Assis, MD

Yale University

Description

Deeper investigations into the pathogenesis of AIH, PBC and PSC requires application of novel tools.  This session highlights new discoveries in human and pre-clinical models of autoimmune and cholestatic disorders by the application of modern sophisticated analyses.

Journey Maps

Presentations

12:00 PM - 12:15 PM
May 19 2026
Washington, D.C.

Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray

Kazumichi Abe, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune
11:15 AM - 11:30 AM
May 19 2026
Washington, D.C.

Candida albicans Contributes to Liver Fibrosis in Primary Sclerosing Cholangitis

Monika Sarkar, MD, FAASLD, MAS , Abstract Presenter
Cholestatic and Autoimmune
11:30 AM - 11:45 AM
May 19 2026
Washington, D.C.

Role of the autophagy inhibitor Rubicon in a PSC mouse model

David N. Assis, MD , Abstract Presenter
Cholestatic and Autoimmune

Objectives

  • Outline the roles played by multiple cell types in the pathogenesis of PBC and PSC.
  • Discuss the findings from new investigations into targets for AIH.
  • Describe the potential roles for fungal products as contributors to the pathogenesis of PSC.